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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERSYNTAX and Derived Coronary Risk Scores 1219
Mayank Yadav, Tullio Palmerini, Adriano Caixeta, Mahesh V. Madhavan, Elias Sanidas,
Ajay J. Kirtane, Gregg W. Stone, Philippe Généreux
The SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score is based on
qualitative and quantitative characterization of coronary artery disease (CAD) by including 11
angiographic variables that take into consideration lesion location and characteristics. The
SYNTAX score has proved to be an effective tool for risk stratiﬁcation of patients with
complex CAD undergoing revascularization. This paper provides an overview of its current
applications, including its integration with other nonangiographic variables into clinical
scores, and explores future applications of the SYNTAX score to guide medical decision
making.MINI-FOCUS:
HIGH-SENSITIVITY TROPONINMINI-FOCUS: HIGH-SENSITIVITY TROPONINSmall Troponin T Change and Mortality in NSTEMI Patients 1231
Christian Bjurman, Mårten Larsson, Per Johanson, Max Petzold, Bertil Lindahl,
Michael L. X. Fu, Ola Hammarsten
Changes in cardiac troponin levels are required for the diagnosis of non–ST-segment
elevation myocardial infarction (NSTEMI), according to the new universal deﬁnition of
acute myocardial infarction. Bjurman and colleagues evaluated changes in troponin T levels in
patients with a clinical diagnosis of NSTEMI using a high-sensitivity cardiac troponin T
(hs-cTnT) assay. After 6 h of observation, the relative change in the hs-cTnT level was
<20% in one-quarter of subjects, and the absolute change was <9 ng/l in 12% of the
NSTEMI patients. A relative hs-cTnT change <20% was linked to higher long-term
mortality compared with patients with higher relative changes. These results show that
a small hs-cTnT change does not identify a low-risk NSTEMI patient.
Editorial Comment: David A. Morrow, Marc P. Bonaca, p. 1239(continued on page A-20)
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Louise Cullen, Christian Mueller, William A. Parsonage, Karin Wildi, Jaimi H. Greenslade,
Raphael Twerenbold, Sally Aldous, Bernadette Meller, Jillian R. Tate, Tobias Reichlin,
Christopher J. Hammett, Christa Zellweger, Jacobus P. J. Ungerer, Maria Rubini Gimenez,
Richard Troughton, Karsten Murray, Anthony F. T. Brown, Mira Mueller, Peter George,
Tamina Mosimann, Dylan F. Flaws, Miriam Reiter, Arvin Lamanna, Philip Haaf,
Christopher J. Pemberton, A. Mark Richards, Kevin Chu, Christopher M. Reid,
William Frank Peacock, Allan S. Jaffe, Christopher Florkowski, Joanne M. Deely, Martin Than
Cullen and colleagues sought to validate the safety of an accelerated diagnostic protocol using
a new high-sensitivity troponin I assay for patients who present to the emergency department
(ED) with chest pain. Blood was retrospectively analyzed from 2 prospective cohorts of ED
patients. The accelerated diagnostic pathway required a normal baseline high-sensitivity
troponin I, a Thrombolysis In Myocardial Infarction (TIMI) risk score 1, and a
nonischemic electrocardiography. A 2-h troponin was then drawn. Nearly 40% of identiﬁed
subjects were low risk per this protocol, and the 30-day major adverse cardiovascular event
rate was 0.8% in these subjects in both the initial and conﬁrmatory cohorts. An early ED
discharge strategy utilizing a high-sensitivity troponin I assay at 0 and 2 h and TIMI score
1 appears to be safe.
Editorial Comment: Alan H. B. Wu, Ann F. Bolger, Judd E. Hollander, p. 1250MINI-FOCUS: HIGH-SENSITIVITY TROPONINHigh-Sensitivity Cardiac Troponin T in HCM 1252
Toru Kubo, Hiroaki Kitaoka, Shigeo Yamanaka, Takayoshi Hirota, Yuichi Baba, Kayo Hayashi,
Tatsuo Iiyama, Naoko Kumagai, Katsutoshi Tanioka, Naohito Yamasaki, Yoshihisa Matsumura,
Takashi Furuno, Tetsuro Sugiura, Yoshinori L. Doi
Kubo and colleagues investigated the signiﬁcance of serum high-sensitivity cardiac troponin T
(hs-cTnT) for the prediction of adverse events in patients with hypertrophic cardiomyopathy
(HCM). Of nearly 200 HCM patients, 54% had elevated hs-cTnT values (>0.014 ng/ml).
During a mean follow-up period of 4.1 years, 32% of the patients with elevated troponin
experienced an adverse cardiac event, compared with only 7% of patients with a normal
hs-cTnT value. An elevated hs-cTnT value remained an independent predictor of
cardiovascular events after multivariate analysis (hazard ratio: 3.2), and the risk of an event
increased in proportion to the level of hs-cTnT. These results show that an elevated hs-cTnT
level is a robust marker of the risk of deterioration in HCM patients.(continued on page A-21)
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Yohei Ohno, Yuichiro Maekawa, Hiroaki Miyata, Soushin Inoue, Shiro Ishikawa, Koichiro Sueyoshi,
Shigetaka Noma, Akio Kawamura, Shun Kohsaka, Keiichi Fukuda
Ohno and colleagues evaluated whether periprocedural bleeding increases the risk of
contrast-induced acute kidney injury (CI-AKI) after percutaneous coronary intervention
(PCI). In a large multicenter registry, 12% of patients developed CI-AKI, deﬁned as an
increase in serum creatinine level 0.5 mg/dl or 25% above baseline values, after PCI. The
risk of CI-AKI correlated closely with the decrement in hemoglobin levels, up to 26% in
those patients who had a >3 g/dl drop. These results suggest that strategies to reduce
periprocedural bleeding may also decrease the risk of CI-AKI.ANTIPLATELET THERAPYAspirin RNA Response Signature 1267
Deepak Voora, Derek Cyr, Joseph Lucas, Jen-Tsan Chi, Jennifer Dungan,
Timothy A. McCaffrey, Richard Katz, L. Kristin Newby, William E. Kraus, Richard C. Becker,
Thomas L. Ortel, Geoffrey S. Ginsburg
To develop ribonucleic acid (RNA) proﬁles for the response to aspirin, Voora and colleagues
administered aspirin followed by whole-blood RNA microarray proﬁling and platelet
function assays to volunteers. Platelet function was assessed by platelet function score (PFS)
or VerifyNow Aspirin Test (Accumetrics, Inc., San Diego, California) in outpatient
cardiology patients. A set of 60 coexpressed genes named the “aspirin response signature”
(ARS) was associated with PFS. Corresponding proteins for 17 ARS genes were identiﬁed in
the platelet proteome, of which, 6 were associated with PFS. These RNA proﬁles of platelet-
speciﬁc genes can be used to identify pathways responsible for both the beneﬁcial effects of
aspirin and to identify those who are resistant to its beneﬁts.
Editorial Comment: Nanette H. Bishopric, p. 1277(continued on page A-22)
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1280Chia-Ying Liu, Yuan-Chang Liu, Colin Wu, Anderson Armstrong, Gustavo J. Volpe,
Rob J. van der Geest, Yongmei Liu, William G. Hundley, Antoinette S. Gomes, Songtao Liu,
Marcelo Nacif, David A. Bluemke, João A. C. Lima
Liu and colleagues evaluated myocardial tissue composition using cardiac magnetic resonance
(CMR) mapping. The T1 mapping techniques used are sensitive to the presence of
myocardial ﬁbrosis. Single slice T1 mapping was performed at the midventricular level before
and at 12 and 25 minutes delay after administration of gadolinium contrast using a Modiﬁed
Look Locker Inversion Recovery (MOLLI) sequence. The results found a consistent, speciﬁc
correlation between T1 indices and age. All CMR indices in men indicated a higher degree
of diffuse myocardial ﬁbrosis with greater age. In women, similar relationships were only
found in models fully adjusted for cardiovascular risk factors and markers of subclinical
cardiovascular diseases. This technique may be useful for further understanding the
development of myocardial ﬁbrosis and, possibly, for monitoring the effects of interventions
to prevent this ﬁbrosis.
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Cynthia A. James, Aditya Bhonsale, Crystal Tichnell, Brittney Murray, Stuart D. Russell,
Harikrishna Tandri, Ryan J. Tedford, Daniel P. Judge, Hugh Calkins
Although animal models and anecdotal evidence suggest that exercise is a risk factor for
arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C), there have been no
systematic human studies. James and colleagues interviewed 87 carriers of desmosomal
mutations for information about regular physical activity from 10 years of age. Endurance
athletes developed symptoms at a younger age (30 years vs. 41 years), were more likely to
meet Task Force Criteria (TFC) at last follow-up (82% vs. 35%), and had a lower lifetime
survival free from ventricular tachycardia/ventricular ﬁbrillation and heart failure. Compared
with those who did the least (lowest quartile) exercise per year before presentation, individuals
in the second (odds ratio [OR]: 6.64), third (OR: 16.7), and top (OR: 25.3) quartiles were
increasingly likely to meet TFC. These ﬁndings conﬁrm that exercise increases the clinical
risk in patients who are carriers of desmosomal mutations and suggest the need to limit
exercise in these patients.(continued on page A-24)
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William O. Roberts, Steven D. Stovitz
Adding electrocardiographic (ECG) screening is being considered by some to reduce cardiac
death rates in young athletes, but the risk of cardiac death of those screened with the current
U.S. Preparticipation Examination (PPE) recommendations are unknown. Roberts and
Stovitz collated data from Minnesota high school athletes who were required to undergo a
standardized PPE every 3 years. There were 4 sudden cardiac deaths (SCDs) in high school
sanctioned games or practices (2 cross country, 1 basketball, 1 wrestling), all male, in
1,666,509 unduplicated athletes participating in 1 or more sports. The incidence of SCD was
thus 0.24 per 100,000 athlete-years over 19 years and 0.11 per 100,000 athlete-years over the
last decade. This incidence is much lower than that observed in studies of Division 1 National
Collegiate Athletic Association and Italian athletes, and the authors contend that further
reductions through mandatory ECG screening are unlikely.
Editorial Comment: Christine E. Lawless, p. 1302
